Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Q32 Bio (QTTB)
NASDAQ:QTTB
Holding QTTB?
Track your performance easily
QTTB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.99 - $53.79
Previous CloseN/A
Volume113.57K
Average Volume (3M)623.83K
Market Cap
$42.88M
Enterprise Value$469.19M
Total Cash (Recent Filing)$11.39M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.21
Shares Outstanding12,180,701
10 Day Avg. Volume183,763
30 Day Avg. Volume623,827
Standard Deviation0.28
R-Squared0.00302
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)37.09
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap10.94
Enterprise Value/Revenue-218.74
Enterprise Value/Gross Profit405.88
Enterprise Value/Ebitda-9.85
Forecast
1Y Price Target
$18.17Price Target Upside457.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Q32 Bio News
PremiumCompany Announcements
Q32 Bio Advances Clinical Trials for Growth Opportunities
PremiumCompany Announcements
Q32 Bio Announces Mixed Results in Clinical Trials
Bulls Say, Bears Say
Bulls Say
Clinical TrialsQ32 Bio's lead clinical programs bempikibart and ADX-097 are in several ongoing clinical trials that provide multiple opportunities for potential significant share appreciation.
Innovation In TreatmentADX-097 tissue-targeted complement mechanism has the potential to address complement dysfunction in multiple indications.
Market PositioningQTTB is seen as well-positioned for success in multiple high-value indications based on the encouraging early data for bempikibart.
Bears Say
Clinical TrialsDisappointing results for lead asset bempikibart from the Phase 2a SIGNAL-AD and SIGNAL-AA studies have led to a downgrade of QTTB's stock rating.
Product DevelopmentThe failure of bempikibart to achieve the primary endpoint in the SIGNAL-AD study has resulted in the removal of value for atopic dermatitis from the company's model.
Resource AllocationThe planned Phase 2 study of the tissue-targeting complement inhibitor ADX-097 has been deferred to fund the alopecia areata expansion trial.
---
Ownership Overview
0.59% Insiders
9.95% Mutual Funds
<0.01% Other Institutional Investors
84.21% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
QTTB FAQ
What was Q32 Bio’s price range in the past 12 months?
Q32 Bio lowest stock price was $2.99 and its highest was $53.79 in the past 12 months.
What is Q32 Bio’s market cap?
Q32 Bio’s market cap is $42.88M.
When is Q32 Bio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Q32 Bio’s earnings last quarter?
Q32 Bio released its earnings results on Aug 08, 2024. The company reported -$1.42 earnings per share for the quarter, missing the consensus estimate of -$0.997 by -$0.423.
Is Q32 Bio overvalued?
According to Wall Street analysts Q32 Bio’s price is currently Undervalued.
Does Q32 Bio pay dividends?
Q32 Bio does not currently pay dividends.
What is Q32 Bio’s EPS estimate?
Q32 Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q32 Bio have?
Q32 Bio has 12,180,701 shares outstanding.
What happened to Q32 Bio’s price movement after its last earnings report?
Q32 Bio reported an EPS of -$1.42 in its last earnings report, missing expectations of -$0.997. Following the earnings report the stock price went down -1.125%.
Which hedge fund is a major shareholder of Q32 Bio?
Currently, no hedge funds are holding shares in QTTB
---
Q32 Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.17 (457.36% Upside)
$18.17 (457.36% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 84.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.02%
12-Months-Change
Fundamentals
Return on Equity
-93.26%
Trailing 12-Months
Asset Growth
-25.36%
Trailing 12-Months
Company Description
Q32 Bio
Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.
---
QTTB Stock 12 Month Forecast
Average Price Target
$18.17
▲(457.36% Upside)
Technical Analysis
Alnylam Pharma
―
Vertex Pharmaceuticals
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering QTTB
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-78.27%
reiterated a buy rating 2 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -78.27% per trade.
---